Halozyme Therapeutics, Inc. (HALO) Coverage Initiated by Analysts at BMO Capital Markets
BMO Capital Markets assumed coverage on shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in a research report report published on Monday. The firm issued a market perform rating and a $14.00 price target on the biopharmaceutical company’s stock.
A number of other equities analysts have also recently commented on HALO. Citigroup Inc set a $14.00 price target on shares of Halozyme Therapeutics and gave the stock a hold rating in a research note on Thursday, January 5th. Zacks Investment Research raised shares of Halozyme Therapeutics from a hold rating to a buy rating and set a $15.00 price target for the company in a research note on Tuesday, January 10th. Piper Jaffray Companies reaffirmed a buy rating and set a $20.00 price target on shares of Halozyme Therapeutics in a research note on Monday, January 23rd. Finally, Deutsche Bank AG lifted their price target on shares of Halozyme Therapeutics from $15.00 to $17.00 and gave the stock a buy rating in a research note on Thursday, March 30th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company. The company presently has an average rating of Hold and an average target price of $13.96.
Shares of Halozyme Therapeutics (NASDAQ:HALO) opened at 13.24 on Monday. The stock has a 50 day moving average price of $13.35 and a 200 day moving average price of $11.88. The firm’s market capitalization is $1.70 billion. Halozyme Therapeutics has a 52 week low of $7.70 and a 52 week high of $15.20.
Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, February 28th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.09. Halozyme Therapeutics had a negative net margin of 44.60% and a negative return on equity of 405.28%. The firm earned $39 million during the quarter, compared to analysts’ expectations of $37.94 million. During the same period in the previous year, the company earned $0.03 EPS. The firm’s revenue for the quarter was down 25.3% compared to the same quarter last year. Analysts forecast that Halozyme Therapeutics will post ($0.96) EPS for the current year.
A number of large investors have recently added to or reduced their stakes in the stock. IFC Holdings Incorporated FL boosted its stake in Halozyme Therapeutics by 2.9% in the third quarter. IFC Holdings Incorporated FL now owns 98,300 shares of the biopharmaceutical company’s stock valued at $1,184,000 after buying an additional 2,800 shares during the period. Taylor Wealth Management Partners bought a new stake in Halozyme Therapeutics during the third quarter valued at about $1,548,000. Chicago Equity Partners LLC bought a new stake in Halozyme Therapeutics during the third quarter valued at about $1,016,000. Synovus Financial Corp bought a new stake in Halozyme Therapeutics during the third quarter valued at about $272,000. Finally, Capital Fund Management S.A. bought a new stake in Halozyme Therapeutics during the third quarter valued at about $2,477,000. 82.94% of the stock is owned by institutional investors.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.